ArticleInternational journal of medical sciences2026
Novel Insight into the Therapeutic Targets for Spinal Degenerative Diseases Gained by a Post-Genome-Wide Association Study.
Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Degenerative spinal diseases are a group of conditions that affect the structure and function of the spine, which can severely impact patient prognosis. Elucidating the druggable genes governing degenerative spinal diseases plays a pivotal role. GWAS data on degenerative spinal diseases, druggable genes, and eQTL data were acquired and Mendelian Randomization (MR) analysis was conducted. Colocalization analysis was performed and the side effects or additional indications of the identified drug targets was assessed using a phenome-wide association study. Finally, the differential expression of druggable genes in different cell subtypes of osteoporosis and intervertebral disc degeneration was analyzed, and molecular docking of actionable drugs for target genes was performed. In total, 31 druggable genes associated with osteoporosis and 22 druggable genes associated with spinal stenosis were identified. Four genes reached significant colocalization in blood for osteoporosis and eleven genes showed colocalization in spinal stenosis blood. Besides GPX1, KLRC2, and TCF19, the other 13 potential therapeutic targets for spinal degenerative diseases had no significant adverse effects. Furthermore, it was found that PAK4 and ESR1 were highly expressed in mesenchymal stem cells (MSCs) derived from bone marrow (BM-MSCs) in osteoporosis samples. SORCS2 expression was higher in nucleus pulposus cells (NPCs) in samples with severe than in samples with mild intervertebral disc degeneration. Lastly, drug analysis supported Fostamatinib might be potential therapeutics for osteoporosis and spinal stenosis by inhibiting PAK4 and PI4KB, respectively. In conclusion, our research suggested that PAK4, ESR1, and PI4KB might be promising targets for spinal degenerative diseases, and the effectiveness of Fostamatinib in these diseases warrants further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.